Literature DB >> 11431360

Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.

M Arcinas1, C A Heckman, J W Mehew, L M Boxer.   

Abstract

A synergistic interaction of Bcl-2 and c-Myc plays a role in lymphomagenesis in mice and in some patients as well. Progression of follicular lymphoma to a more aggressive lymphoma is seen in the majority of patients, and approximately 10% of the transformed lymphomas have a translocation of c-myc in addition to the translocation of bcl-2 found in the original follicular lymphoma. We investigated whether transcriptional deregulation of bcl-2 and c-myc could be examined in primary lymphoma cells by in vivo footprinting and in vitro protein-DNA binding studies. A matched pair of follicular and transformed lymphoma samples was examined. The transformed lymphoma had acquired a translocation of c-myc into the immunoglobulin heavy chain locus. High levels of bcl-2 expression were observed in both the follicular and transformed lymphomas, whereas the expression of c-myc was low in the follicular lymphoma and increased in the transformed lymphoma. In vivo footprint analysis revealed that a CRE site and a Cdx site in the bcl-2 promoter were occupied on the translocated alleles but not on the normal alleles in both the follicular and transformed lymphomas. Two nuclear factor kappaB sites were occupied on the translocated c-myc allele in the transformed lymphoma. Gel shift analysis revealed that these proteins bound to their respective sites in the bcl-2 or c-myc promoter. There was no evidence that the presence of one of the translocations in the immunoglobulin heavy chain locus influenced the expression of the other translocated gene.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431360

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

3.  Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma.

Authors:  James R Cerhan; Stephen M Ansell; Zachary S Fredericksen; Neil E Kay; Mark Liebow; Timothy G Call; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Wen Liu-Mares; William R Macon; Diane Jelinek; Thomas E Witzig; Thomas M Habermann; Susan L Slager
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

4.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

5.  CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.

Authors:  Kathleen M Sakamoto; David A Frank
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex.

Authors:  Rong-Jun Guo; Shinsuke Funakoshi; Hannah H Lee; Jianping Kong; John P Lynch
Journal:  Carcinogenesis       Date:  2009-09-04       Impact factor: 4.944

Review 7.  Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.

Authors:  Walter Douglas Fairlie; Erinna F Lee
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

8.  CREB: A Key Regulator of Normal and Neoplastic Hematopoiesis.

Authors:  Salemiz Sandoval; Martina Pigazzi; Kathleen M Sakamoto
Journal:  Adv Hematol       Date:  2009-08-27

9.  Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells.

Authors:  Pinella Buongiorno; Vaijayanti V Pethe; George S Charames; Susmita Esufali; Bharati Bapat
Journal:  Mol Cancer       Date:  2008-09-30       Impact factor: 27.401

10.  Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.

Authors:  Yuanhui Liu; Nancy G Azizian; Yaling Dou; Lan V Pham; Yulin Li
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.